(1S,2S,4R)-2-Bicyclo[2.2.1]hept-2-yl-isoindole-1,3-dione | 217093-67-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异吲哚及其衍生物
• 英文名称: (1S,2S,4R)-2-Bicyclo[2.2.1]hept-2-yl-isoindole-1,3-dione
• 英文别名: (1S,2S,4R)-2-bicyclo[2.2.1]hept-2-yl isoindole-1,3-dione；2-[(1S,2S,4R)-2-bicyclo[2.2.1]heptanyl]isoindole-1,3-dione
• CAS: 217093-67-9
• 化学式: C₁₅H₁₅NO₂
• 分子量: 241.29
• InChiKey: NTGHOUCYJCXRFM-NRUUGDAUSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  18
• 可旋转键数：
  1
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  37.4
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (1S,2S,4R)-2-Bicyclo[2.2.1]hept-2-yl-isoindole-1,3-dione 在 肼 作用下， 以 甲醇 为溶剂， 生成 (+)-(1S,2S,4R)-2-norbornylamine
  参考文献：
  名称：

  Potent quinoxaline-Based inhibitors of PDGF receptor tyrosine kinase activity. Part 1: SAR Exploration and Effective Bioisosteric Replacement of a phenyl substituent

  摘要：

  Novel substituted 2-anilino- and 2-cycloalkylaminoquinoxalines have been found to be useful and selective inhibitors of PDGF-R autophosphorylation. Replacement of an anilino-substituent with substituted cyclohexylamino- or norbornylamino substituents led to significant improvements in the pharmacokinetic profile of these analogues. (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(03)00654-1
• 作为产物：
  描述：

  邻苯二甲酸亚胺 、 (2R)-(+)-桥-降冰片 在 三苯基膦 、 偶氮二甲酸二乙酯 作用下， 以95%的产率得到(1S,2S,4R)-2-Bicyclo[2.2.1]hept-2-yl-isoindole-1,3-dione
  参考文献：
  名称：

  Potent quinoxaline-Based inhibitors of PDGF receptor tyrosine kinase activity. Part 1: SAR Exploration and Effective Bioisosteric Replacement of a phenyl substituent

  摘要：

  Novel substituted 2-anilino- and 2-cycloalkylaminoquinoxalines have been found to be useful and selective inhibitors of PDGF-R autophosphorylation. Replacement of an anilino-substituent with substituted cyclohexylamino- or norbornylamino substituents led to significant improvements in the pharmacokinetic profile of these analogues. (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(03)00654-1

文献信息

• Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases
  申请人：——

  公开号：US20030130285A1

  公开（公告）日：2003-07-10

  This invention is directed to quinoline/quinoxaline compounds which inhibit platelet-derived growth factor or p56 lck tyrosine kinase activity, to pharmaceutical compositions comprising these compounds, and to the use of these compounds for treating a patient suffering from or subject to disorders/conditions involving cellular differentiation, proliferation, extracellular matrix production or mediator release and/or T cell activation and proliferation.

  本发明涉及抑制血小板源性生长因子或p56lck酪氨酸激酶活性的喹啉/喹噁啉化合物，以及包含这些化合物的制药组合物，以及使用这些化合物治疗患有或患有涉及细胞分化、增殖、细胞外基质产生或介质释放和/或T细胞激活和增殖的疾病/症状的患者。
• Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and /or p56lck tyrosine kinases
  申请人：——

  公开号：US20030139400A1

  公开（公告）日：2003-07-24

  This invention is directed to quinoline/quinoxaline compounds which inhibit platelet-derived growth factor or p56 lck tyrosine kinase activity, to pharmaceutical compositions comprising these compounds, and to the use of these compounds for treating a patient suffering from or subject to disorders/conditions involving cellular differentiation, proliferation, extracellular matrix production or mediator release and/or T cell activation and proliferation.

  本发明涉及抑制血小板源性生长因子或p56lck酪氨酸激酶活性的喹啉/喹噁啉化合物，以及包含这些化合物的制药组合物，并且涉及使用这些化合物治疗患有或存在细胞分化、增殖、细胞外基质产生或介质释放和/或T细胞激活和增殖的疾病/状况的患者。
• US06180632B2
  申请人：——

  公开号：——

  公开（公告）日：——
• US6180632B1
  申请人：——

  公开号：US6180632B1

  公开（公告）日：2001-01-30
• US6852712B2
  申请人：——

  公开号：US6852712B2

  公开（公告）日：2005-02-08